Aldosterone and angiotensin II profiles in young black and white women using different hormonal contraceptives: the African-PREDICT study.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
28
08
2020
accepted:
15
06
2021
revised:
29
05
2021
pubmed:
27
6
2021
medline:
16
8
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
Exogenous estrogens and progestins may affect the components of the renin-angiotensin-aldosterone system (RAAS). Changes in ventricular blood volume are associated with increased secretion of N-terminal pro-hormone B-type natriuretic peptide (NT-proBNP), which may also be affected by hormonal contraceptives. In this study, we aimed to compare components of the RAAS and NT-proBNP between groups using different hormonal contraceptives, including the combination pill, the injection or implant, and controls (no contraception) in black and white women of fertile age (20 - 30 years). Secondly, we determined whether blood pressure and NT-proBNP are associated with the RAAS components. We included 397 black and white women not using contraceptives, 120 using the combination pill, and 103 receiving an injection/implant. RAAS Triple-A analysis was carried out with LC-MS/MS quantification, and blood pressure measurements (ABPM) taken over 24 h. We found that serum aldosterone was higher (475.7 vs. 249.2 pmol/L; p < 0.001) in the combination pill group than in the no contraception group of white women. The aldosterone-angiotensin II ratio (AA2) was higher (5.4 vs. 2.5; p < 0.001) in the combination pill group than in the no contraception group. In the black women using the combination pill, we found a borderline-positive and borderline-negative association between 24-h systolic blood pressure and NT-proBNP with equilibrium (eq) Ang II, respectively. In white women using the combination pill, only CRP contributed positively and independently to NT-proBNP. To conclude, activation of RAAS by different hormonal contraceptives may increase future risk for the development of hypertension in young black and white women.
Identifiants
pubmed: 34172825
doi: 10.1038/s41371-021-00569-6
pii: 10.1038/s41371-021-00569-6
doi:
Substances chimiques
Contraceptive Agents
0
Angiotensin II
11128-99-7
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-717Subventions
Organisme : Medical Research Council
ID : MC_PC_16095
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Chersich MF, Wabiri N, Risher K, Shisana O, Celentano D, Rehle T, et al. Contraception coverage and methods used among women in South Africa: a national household survey. S Afr Med J. 2017;107:307–14.
doi: 10.7196/SAMJ.2017.v107i4.12141
Stephenson R, Beke A, Tshibangu D. Community and health facility influences on contraceptive method choice in the Eastern Cape, South Africa. Int Fam Plan Perspect. 2008;34:62–70.
doi: 10.1363/3406208
Kaida A, Laher F, Strathdee SA, Money D, Janssen PA, Hogg RS, et al. Contraceptive use and method preference among women in Soweto, South Africa: the influence expanding access HIV care treat service. PLoS ONE. 2010;5:e13868. November
doi: 10.1371/journal.pone.0013868
Contraception. Human reproduction programme (HRP), World Health Organization, WHO/RHR/14.07_eng. [Accessed 2020, Apr.]
United Nations, Department of Economic and Social Affairs, Population Division. World Family Planning. 2017 - Highlights (ST/ESA/SER.A/414). [Accessed 2020, March].
Woods JW. Oral contraceptives and hypertension. Hypertension 1988;11:11–15.
doi: 10.1161/01.HYP.11.3_Pt_2.II11
Ribeiro CCM, Shimo AKK, de M, Lopes MHB, Lamas JLT. Effect of different hormonal contraceptives in women’s blood pressure values. Rev Bras Enferm [Internet]. 2018;71:1453–9.
doi: 10.1590/0034-7167-2017-0317
Harvey RE, Hart EC, Charkoudian N, Curry TB, Carter JR, Fu Q, et al. Oral contraceptive use, muscle sympathetic nerve activity, and systemic hemodynamics in young women. Hypertension. 2015;66:590–7.
doi: 10.1161/HYPERTENSIONAHA.115.05179
Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effects of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011;96:1797–804.
doi: 10.1210/jc.2010-2918
Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58:618–26.
doi: 10.1016/j.jacc.2011.03.042
Baughman KL. B-Type natriuretic peptide – a window to the heart. N. Engl J Med. 2002;347:158–9.
doi: 10.1056/NEJMp020057
Rayner BL, Spence D. Hypertension in blacks: insights from Africa. J Hypertens. 2017;35:234–9.
doi: 10.1097/HJH.0000000000001171
du Toit WL, Schutte AE, Gafane-Matemane LF, Kruger R, Mels CMC. The renin-angiotensin-system and left ventricular mass in young adults: the African-PREDICT study. Blood Pressure. 2020;30:98–107. https://doi.org/10.1080/08037051.2020.1831902 .
Schutte AE, Gona PN, Delles C, Uys AS, Burger A, Mels CM, et al. The African prospective study on the early detection and Identification of cardiovascular disease and hypertension (African-PREDICT, Design, recruitment and initial examination. Europ J of Prevent Cardiol. 2019;26:458–70.
Department of health, Pretoria, South Africa. National contraception clinical guidelines. 2012. www.doh.gov.za . [Accessed 2020, Nov.]
Marfell-Jones M, Olds T, Stewart A, Carter L. International standards for anthropometric assessment. International Society for the Advancement of Kinanthropometry; 2006. p. 137.
Patro BK, Jeyashree K, Gupta PK. Kuppuswam’s Socioeconomic Status Scale 2010 – the need for periodic revision. Indian J Pediatr. 2012;79:395–6.
doi: 10.1007/s12098-011-0517-7
Hayashi I, Morishita Y, Imai K, Nakamura M, Nakachi K, Hayashi T. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res. 2007;631:55–61.
doi: 10.1016/j.mrgentox.2007.04.006
Odutayo A, Cherney D, Miller J, Ahmed SB, Lai V, Dunn S, et al. Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women. Am J Physiol Ren Physiol. 2015;308:F535–40.
doi: 10.1152/ajprenal.00602.2014
Burrello J, Gai C, Tetti M, Lopatina T, Deregibus MC, Veglio F, et al. Characterization and gene expression analysis of serum derived extracellular vesicles in primary aldosteronism. Hypertension 2019;74:359–67.
doi: 10.1161/HYPERTENSIONAHA.119.12944
Stowasser M, Ahmed A, Guo Z, Wolley M, Ungerer J, McWhinney B, et al. Can screening and confirmatory testing in the management of patients with primary aldosteronism be improved? Horm Metab Res. 2017;49:915–21.
doi: 10.1055/s-0043-121468
Van Rooyen JM, Poglitsch M, Huisman HW, Gafane-Matemane LF, Breet Y, Malan L. A primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in black men: the SABPA study. Cardiovasc J Afr. 2019;30:1–6.
Kuroski de Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res. 1999;41:524–31.
doi: 10.1016/S0008-6363(98)00324-1
Lee CYW, Burnett JC. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131–42.
doi: 10.1007/s10741-007-9016-3
Divani AA, Luo X, Datta YH, Flaherty JD, Panoskaltsis-Mortari A. Effect of oral and vaginal hormonal contraceptives on inflammatory blood biomarkers. Mediators Inflamm. 2015;2015:379501.
doi: 10.1155/2015/379501